Awarix

Awarix is a pre-clinical stage biotechnology company dedicated to developing novel small molecule therapeutics for the treatment of bone-related diseases and hematologic malignancies. Founded by researchers from the University of Alabama at Birmingham (UAB), the company's primary focus is on inhibiting heparanase, an enzyme that plays a critical role in tumor growth, metastasis, and bone degradation. Their lead programs aim to address significant unmet needs in multiple myeloma and cancer-induced bone disease by preserving bone integrity and inhibiting tumor progression. Awarix leverages deep expertise in glycobiology and bone remodeling to advance its pipeline of targeted inhibitors. The company has been supported by federal research grants and regional innovation awards to transition its academic discoveries into clinical candidates.